CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer's drug
Bristol Myers Squibb, BeiGene, AstraZeneca and Pfizer secured European backing for label expansions, and a French pharma got its first drug approval recommendation, in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
